Diasome Pharmaceuticals
Phase 3Diasome’s HDV™ platform redefines drug delivery by targeting the liver, improving treatment for diabetes, obesity, and metabolic dysfunction.
Founded
1999
Focus
BiologicsSmall Molecules
About
Diasome’s HDV™ platform redefines drug delivery by targeting the liver, improving treatment for diabetes, obesity, and metabolic dysfunction.
Funding History
3Total raised: $32M
Grant$2MNational Institutes of HealthJun 15, 2021
Series B$20MUndisclosedJun 15, 2020
Series A$10MUndisclosedJun 15, 2018
Company Info
TypePrivate
Founded1999
LocationCleveland, United States
StagePhase 3
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile